CYP3A5 polymorphism effect on cyclosporine pharmacokinetics in living donor renal transplant recipients: Analysis by population pharmacokinetics;Effet du polymorphisme du CYP3A5 sur la pharmacocinétique de la cyclosporine chez les transplantés rénaux: Analyse de pharmacocinétique de population

Annals of Pharmacotherapy

Volumn 46, Issue 9, 2012, Pages 1141-1151

  Song, Joohan ^a   Kim, Myeong Gyu ^a   Choi, Boyoon ^a   Han, Na Young ^a   Yun, Hwi Yeol ^b   Yoon, Jeong Hyun ^c   Oh, Jung Mi ^a  

^a Seoul National University   (South Korea)

^b Choongwae Pharma Co   (South Korea)

^c Pusan National University   (South Korea)

Author keywords

Cyclosporine; CYP3A5; Kidney transplantation; Pharmacogenetics; Pharmacokinetics; Population genetic polymorphism

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; CYTOCHROME P450 3A5; METHYLPREDNISOLONE; MULTIDRUG RESISTANCE PROTEIN 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE;

ADULT; ARTICLE; BLOOD SAMPLING; CONCENTRATION RESPONSE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG ELIMINATION; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADULT; CYCLOSPORINE; CYTOCHROME P-450 CYP3A; FEMALE; GENOTYPE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; MODELS, BIOLOGICAL; POLYMORPHISM, GENETIC;

EID: 84865853261     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1R004     Document Type: Article

References (39)

1. A randomized clinic, Santos-Buelga D, Dominguez-Gil A, Garcia MJ. Immunosuppressive therapy for paediatric transplant patients: pharmacokinetic considerations. Clin Pharmacokinet 2002;41:115-35.
2. Ponticelli C, Minetti L, Di Palo FQ, et al. The Milan clinical trial with cyclosporine in cadaveric renal transplantation. A three-year follow-up. Transplantation 1988;45:908-13.
3. Kahan BD. Therapeutic drug monitoring of cyclosporine: 20 years of progress. Transplant Proc 2004;36:378S-91S.
4. Rodrigo E, Ruiz JC, Angeles de Cos M, et al. Correlation of C0 and C2 levels with cyclosporine side effects in kidney transplantation. Transplant Proc 2009;41:2328-31.
5. Wu KH, Cui YM, Guo JF, et al. Population pharmacokinetics of cyclosporine in clinical renal transplant patients. Drug Metab Dispos 2005; 33:1268-75.
6. McMillan MA. Clinical pharmacokinetics of cyclosporin. Pharmacol Ther 1989;42:135-56.
7. Akhlaghi F, Trull AK. Distribution of cyclosporin in organ transplant recipients. Clin Pharmacokinet 2002;41:615-37.
8. Wasan KM, Pritchard PH, Ramaswamy M, Wong W, Donnachie EM, Brunner LJ. Differences in lipoprotein lipid concentration and composition modify the plasma distribution of cyclosporine. Pharm Res 1997;14: 1613-20.
9. Hebert MF, Roberts JP, Prueksaritanont T, Benet LZ. Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther 1992;52:453-7.
10. Ducharme MP, Warbasse LH, Edwards DJ. Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin Pharmacol Ther 1995;57:485-91.
11. Ubhi CS, Woodhouse L, Giles GR. Interaction of intravenous methylprednisolone with oral cyclosporin. Nephrol Dial Transplant 1990;5:376-8.
12. Rosenbaum SE, Baheti G, Trull AK, Akhlaghi F. Population pharmacokinetics of cyclosporine in cardiopulmonary transplant recipients. Ther Drug Monit 2005;27:116-22.
13. del Mar Fernandez De Gatta M, Santos-Buelga D, Dominguez-Gil A, Garcia MJ. Immunosuppressive therapy for paediatric transplant patients: pharmacokinetic considerations. Clin Pharmacokinet 2002;41:115-35.
14. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001;27:383-91.
15. Sakaeda T, Nakamura T, Okumura K. Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs. Pharmacogenomics 2003;4:397-410.
16. Yates CR, Zhang W, Song P, et al. The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. J Clin Pharmacol 2003;43:555-64.
17. Hesselink DA, van Gelder T, van Schaik RH, et al. Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes. Clin Pharmacol Ther 2004;76:545-56.
18. Bos EM, Leuvenink HG, van Goor H, Ploeg RJ. Kidney grafts from brain dead donors: Inferior quality or opportunity for improvement? Kidney Int 2007;72:797-805.
19. Sanchez-Fructuoso A, Naranjo Garcia P, Calvo Romero N, et al. Effect of the brain-death process on acute rejection in renal transplantation. Transplant Proc 2007;39:2214-6.
20. Rojas-Pena A, Reoma JL, Krause E, et al. Extracorporeal support: improves donor renal graft function after cardiac death. Am J Transplant 2010;10:1365-74.
21. Lacy CF, Amstrong LL, Goldman MP, Lance LL. Drug information handbook. 20th ed. Hudson, Ohio: Lexi-Comp, 2011-2012:396-400.
22. Nishimura M, Yoshitsugu H, Naito S, Hiraoka I. Evaluation of gene induction of drug-metabolizing enzymes and transporters in primary culture of human hepatocytes using high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi 2002;122:339-61.
23. Cascorbi I, Gerloff T, Johne A, et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 2001;69:169-74.
24. Beal S, Sheiner LB, Boeckmann A, et al. NONMEM user's guides (1989-2009) Ellicott City, Icon Development Solutions; 2009.
25. Parke J, Charles BG. NONMEM population pharmacokinetic modeling of orally administered cyclosporine from routine drug monitoring data after heart transplantation. Ther Drug Monit 1998;20:284-93.
26. Tan KK, Trull AK, Hue KL, Best NG, Wallwork J, Higenbottam TW. Pharmacokinetics of cyclosporine in heart and lung transplant candidates and recipients with cystic fibrosis and Eisenmenger's syndrome. Clin Pharmacol Ther 1993;53:544-54.
27. Parke J, Charles BG. Factors affecting oral cyclosporin disposition after heart transplantation: bootstrap validation of a population pharmacokinetic model. Eur J Clin Pharmacol 2000;56:481-7.
28. Rui JZ, Zhuo HT, Jiang GH, Chen G. [Evaluation of population pharmacokinetics of cyclosporin A in renal transplantation patients with NONMEM]. Yao Xue Xue Bao 1995;30:241-7.
29. Chen B, Zhang W, Gu Z, Li J, Zhang Y, Cai W. Population pharmacokinetic study of cyclosporine in Chinese renal transplant recipients. Eur J Clin Pharmacol 2011;67:601-12.
30. Product Information. Neoral soft gelatin capsules (cyclosporine capsule, USP) modified, Neoral oral solution (cyclosporine oral solution, USP) modified. East Hanover, NJ: Novartis Pharmaceuticals Corp., October 2009.
31. Zhu HJ, Yuan SH, Fang Y, Sun XZ, Kong H, Ge WH. The effect of CYP3A5 polymorphism on dose-adjusted cyclosporine concentration in renal transplant recipients: a meta-analysis. Pharmacogenomics J 2011; 11:237-46.
32. Kim SH, Kim KI, Yun HY, et al. Population pharmacokinetics of cyclosporine after hematopoietic stem cell transplantation in leukemic patients. Korean J Clin Pharm 2010;20:9-16.
33. Irtan S, Saint-Marcoux F, Rousseau A, et al. Population pharmacokinetics and Bayesian estimator of cyclosporine in pediatric renal transplant patients. Ther Drug Monit 2007;29:96-102.
34. Kahan BD, Kramer WG, Wideman C, Flechner SM, Lorber MI, Van Buren CT. Demographic factors affecting the pharmacokinetics of cyclosporine estimated by radioimmunoassay. Transplantation 1986;41:459-64.
35. Kelly P, Kahan BD. Review: metabolism of immunosuppressant drugs. Curr Drug Metab 2002;3:275-87.
36. Klintmalm G, Sawe J. High dose methylprednisolone increases plasma cyclosporin levels in renal transplant recipients. Lancet 1984;1:731.
37. Soldin OP, Chung SH, Mattison DR. Sex differences in drug disposition. J Biomed Biotechnol 2011. doi: 10.1155/2011/187103
38. Mathis AS, Friedman GS, Knipp GT. Do sex and ethnicity influence drug pharmacokinetics in solid organ transplantation? Graft 2002;5:294-302.
39. Molpeceres J, Chacon M, Berges L, Pedraz JL, Guzuman M, Aberturas MR. Age and sex dependent pharmacokinetics of cyclosporine in the rat after a single intravenous dose. Int J Pharm 1998;174:9-19.